Patents by Inventor Youzhen Wang

Youzhen Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20220016118
    Abstract: A combination of (a) Midostaurin, or a pharmaceutically acceptable salt thereof, or a complex thereof, or a co-crystal thereof, or a solvate, including hydrate, thereof, and (b) a Mcl-1 inhibitor and compositions and uses thereof.
    Type: Application
    Filed: November 14, 2019
    Publication date: January 20, 2022
    Inventors: Ensar HALILOVIC, Youzhen WANG, Erick MORRIS, Marina KONOPLEVA, Anna SKWARSKA
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20210386763
    Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.
    Type: Application
    Filed: December 18, 2019
    Publication date: December 16, 2021
    Inventors: Nelson GUERREIRO, Ensar HALILOVIC, Astrid JULLION, Christophe MEILLE, Youzhen WANG
  • A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND AN ERK INHIBITOR
    Publication number: 20210121460
    Abstract: The present invention relates to a pharmaceutical combination comprising dabrafenib, trametinib and an Erk-inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Matthew John Meyer, Youzhen Wang
  • Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190240225
    Abstract: A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 8, 2019
    Applicants: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Andrew WEI, Donia MOUJALLED, Giovanna POMILIO, Ana Leticia MARAGNO, Olivier GENESTE, Audrey CLAPERON, Heiko MAACKE, Ensar HALILOVIC, Dale PORTER, Erick MORRIS, Youzhen WANG, Sneha SANGHAVI, Prakash MISTRY
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof
    Patent number: 8906936
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: December 9, 2014
    Assignee: Novartis AG
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • ANTI-CXCR4 ANTIBODIES AND METHODS OF USE
    Publication number: 20140314784
    Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 23, 2014
    Applicant: Medlmmune Limited
    Inventors: Vahe Bedian, Youzhen Wang, Ian Foltz, Palaniswami Rathanaswami, Jaspal Singh Kang, Adeela Kamal, Philipp Steiner
  • COMBINATION OF AN IAP INHIBITOR AND A TAXANE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE
    Publication number: 20130085153
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: July 12, 2012
    Publication date: April 4, 2013
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER
    Publication number: 20110092388
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 21, 2011
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas system
    Inventors: JAMES LILLIE, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yong Yao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai
  • Combinations of Organic Compounds
    Publication number: 20100324083
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: August 25, 2010
    Publication date: December 23, 2010
    Inventors: Michael Rugaard JENSEN, Christopher Sean STRAUB, Leigh ZAWEL, Mary Ann TRAN, Youzhen WANG
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER
    Publication number: 20100105051
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 29, 2010
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: JAMES LILLIE, MANJULA GANNAVARAPU, KAREN GLATT, SEBASTIAN HOERSCH, SHUBHANGI KAMATKAR, MAUREEN MERTENS HATTERSLEY, JOHN E. MONAHAN, VICKESH MYER, YOUZHEN WANG, YONG YAO XU, XUMEI ZHAO, RACHEL E. MEYERS, ROBERT C. BAST, JR., GABRIEL N. HORTOBAGYI, LAJOS PUSZTAI
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Patent number: 7705120
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: April 27, 2010
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, Jr., Gabriel N. Hortobagyi, Lajos Pusztai
  • Combinations of Organic Compounds
    Publication number: 20090005411
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: December 18, 2006
    Publication date: January 1, 2009
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20080311573
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: June 25, 2007
    Publication date: December 18, 2008
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills
  • Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer
    Publication number: 20030215805
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of breast cancer.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 20, 2003
    Applicant: Millennium Pharmaceutical, Inc.
    Inventors: James Lillie, Adam Palermo, Youzhen Wang, Kathleen Steinmann, Josh Elias, Maureen Mertens
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20030124128
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: June 21, 2002
    Publication date: July 3, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills
  • Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20030099974
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Application
    Filed: July 18, 2002
    Publication date: May 29, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: James Lillie, Yongyao Xu, Youzhen Wang, Kathleen Steinmann